Immunomodulatory mesenchymal cells useful in myasthenia gravis

A group of researchers coordinated by the Institute of Myology has focused on a small contingent of cells and their potential use in the treatment of myasthenia gravis (MG):

• these stromal cells derive from the mesenchyme and play a role in regulating immunomodulation when they are brought into contact with mononuclear blood cells,
• several functional approaches ranging from RNA-Seq to mass and flow cytometry, including secretome analysis, were used.
• studies of this cell population were carried out in a basal state, in the presence of the mononuclear cells in question, or following stimulation by interferon gamma, all in vitro« Dans le verre », expériences réalisées en laboratoire en dehors de l’organisme. and in MG animal models.
• The different transcriptomic profiles obtained confirm the beneficial nature of this cell contingent.

Although very fundamental, this work could ultimately lead to new therapeutic avenues in MG.

Mesenchymal stromal cells conditioned by peripheral blood mononuclear cells exert enhanced immunomodulation capacities and alleviate a model of Myasthenia Gravis. Bayer AC, Pinzón N, You A et al. Stem Cell Res Ther. 2025 Aug